(3aR,6aS)-tert-butyl 5-(6-chloropyridazin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate | 1173179-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3aR,6aS)-tert-butyl 5-(6-chloropyridazin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
• 英文别名: tert-butyl 5-(6-chloropyridazin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate；t-butyl cis-5-(6-chloro-pyridazin-3-yl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylate；tert-butyl (3aR,6aS)-2-(6-chloropyridazin-3-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate
• CAS: 1173179-68-4
• 化学式: C₁₅H₂₁ClN₄O₂
• 分子量: 324.81
• InChiKey: GGQMEOLWXRPRNJ-PHIMTYICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3aR,6aS)-tert-butyl 5-(6-chloropyridazin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 氯(2-二环己基膦基-2',4′,6′-三异丙基-1,1′-联苯基)[2-(2-氨基乙基)苯基)]钯(II) 、 sodium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 (3aR,6aS)-tert-butyl 5-(6-(2-hydroxy-4-(1H-pyrazol-4-yl)phenyl)pyridazin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  [EN] 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS
  [FR] ANALOGUES DE PYRIDAZINE 1,4-DISUBSTITUÉE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES LIÉS À UNE DÉFICIENCE EN SMN

  摘要：

  本发明提供了一种公式(I)的化合物或其药用可接受的盐；一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。

  公开号：

  WO2014028459A1
• 作为产物：
  描述：

  3,6-二氯哒嗪 、 tert-butyl (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 正丁醇 为溶剂， 反应 2.0h， 以70%的产率得到(3aR,6aS)-tert-butyl 5-(6-chloropyridazin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  [EN] 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS
  [FR] ANALOGUES DE PYRIDAZINE 1,4-DISUBSTITUÉE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES LIÉS À UNE DÉFICIENCE EN SMN

  摘要：

  本发明提供了一种公式(I)的化合物或其药用可接受的盐；一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。

  公开号：

  WO2014028459A1

文献信息

• 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS
  申请人：CHEUNG Atwood Kim

  公开号：US20140051672A1

  公开（公告）日：2014-02-20

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了公式I的化合物或其药学上可接受的盐；制备本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
  申请人：Cheung Atwood Kim

  公开号：US08729263B2

  公开（公告）日：2014-05-20

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了公式I的化合物或其药学上可接受的盐；一种制造该发明化合物的方法以及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions
  申请人：Novartis AG

  公开号：US11229648B2

  公开（公告）日：2022-01-25

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种式 I 的化合物或其药学上可接受的盐； 一种制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂组合和药物组合物。
• Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)
  作者：Atwood K. Cheung、Brian Hurley、Ryan Kerrigan、Lei Shu、Donovan N. Chin、Yiping Shen、Gary O’Brien、Moo Je Sung、Ying Hou、Jake Axford、Emma Cody、Robert Sun、Aleem Fazal、Cary Fridrich、Carina C. Sanchez、Ronald C. Tomlinson、Monish Jain、Lin Deng、Keith Hoffmaster、Cheng Song、Mailin Van Hoosear、Youngah Shin、Rebecca Servais、Christopher Towler、Marc Hild、Daniel Curtis、William F. Dietrich、Lawrence G. Hamann、Karin Briner、Karen S. Chen、Dione Kobayashi、Rajeev Sivasankaran、Natalie A. Dales

  DOI：10.1021/acs.jmedchem.8b01291

  日期：2018.12.27

  Spinal muscular atrophy (SMA), a rare neuromuscular disorder, is the leading genetic cause of death in infants and toddlers. SMA is caused by the deletion or a loss of function mutation of the survival motor neuron 1 (SMN1) gene. In humans, a second closely related gene SMN2 exists; however it codes for a less stable SMN protein. In recent years, significant progress has been made toward disease modifying treatments for SMA by modulating SMN2 pre-mRNA splicing. Herein, we describe the discovery of LMI070/branaplam, a small molecule that stabilizes the interaction between the spliceosome and SMN2 pre-mRNA. Branaplam (1) originated from a high-throughput phenotypic screening hit, pyridazine 2, and evolved via multiparameter lead optimization. In a severe mouse SMA model, branaplam treatment increased full-length SMN RNA and protein levels, and extended survival. Currently, branaplam is in clinical studies for SMA.
• Octahydropyrrolo[3,4-<i>c</i>]pyrrole: A Diamine Scaffold for Construction of Either α4β2 or α7-Selective Nicotinic Acetylcholine Receptor (nAChR) Ligands. Substitutions that Switch Subtype Selectivity
  作者：William H. Bunnelle、Karin R. Tietje、Jennifer M. Frost、Dan Peters、Jianguo Ji、Tao Li、Marc J. C. Scanio、Lei Shi、David J. Anderson、Tino Dyhring、Jens H. Grønlien、Hilde Ween、Kirsten Thorin-Hagene、Michael D. Meyer

  DOI：10.1021/jm900249k

  日期：2009.7.23

  A series of 5-(pyridine-3-yl)octahydropyrrolo[3,4-c]pyrroles have been prepared that exhibit high affinity to alpha 4 beta 2 and/or alpha 7 nicotinic acetylcholine receptors (nAChRs). Simple substitution patterns have been identified that allow construction of ligands that are highly selective for either nAChR subtype. The effects of substitution on subtype selectivity provide some insight into the differences in the ligand binding domains of the alpha 4 beta 2 and alpha 7 receptors, especially in regions removed from the cation binding pocket.